News

Under the terms of the letter of intent, Sigma-Tau has purchased $1.5 million of Dor’s common stock at the market price of $0.09 per share, which will be

Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need. A Prescription Drug User Fee Act target date of April 2,

The agreement makes Cardinal Health the exclusive manufacturer of SRI Surgical’s complete line of more than 400 disposable surgical kits. In addition, the agreement provides for the development

The marketing authorization application (MAA) for Cerepro, filed following a pre-submission meeting with the European medicines regulatory agency (EMEA), will now enter the validation stage, prior to commencing

Advanced Cell Technology (ACTC) will exclusively license to the joint venture, which will be majority owned by CHA, all of its hemangioblast technology. CHA will contribute working capital

The cethromycin new drug application (NDA) is based on a full clinical development and manufacturing program for cethromycin. The program included two global Phase III pivotal studies for

Under the terms of the agreement, Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin, for the continued development and commercialization of ConjuChem’s PC-DAC:Exendin-4. The agreement calls

Neat is said to be a versatile genomics testing platform that enables gene-controlled ligation of oligonucleotide probes inside of cells. This highly specific technique will be used to

Lescarden’s Catrix Wound Dressing utilizes bovine cartilage that has been refined into a fine, white powder. It has been shown in extensive clinical testing to be an effective